In Vivo pharmacokinetics and pharmacodynamics of ZTI-01 (fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, klebsiella pneumoniae, and pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 6, 2017, Pages

  Lepak, Alexander J ^a   Zhao, Miao ^a,b,c   Vanscoy, Brian ^d   Taylor, Daniel S ^d   Ellis Grosse, Evelyn ^e   Ambrose, Paul G ^d   Andes, David R ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^d INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^e Zavante Therapeutics   (United States)

Author keywords

Fosfomycin; PK PD

Indexed keywords

FOSFOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; ESCHERICHIA COLI; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; THIGH; ANIMAL; DRUG EFFECTS; FEMALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; FEMALE; FOSFOMYCIN; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; THIGH;

EID: 85019761467     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00476-17     Document Type: Article

References (33)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. https://doi.org/10.1086/595011.
2. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr, Infectious Diseases Society of America. 2008. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164. https://doi.org/10.1086/524891.
3. Cassir N, Rolain JM, Brouqui P. 2014. A new strategy to fight antimicrobial resistance: The revival of old antibiotics. Front Microbiol 5:551. https://doi.org/10.3389/fmicb.2014.00551.
4. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. 2012. 'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis 25:626-633. https://doi.org/10.1097/QCO.0b013e328358afe5.
5. Skarzynski T, Mistry A, Wonacott A, Hutchinson SE, Kelly VA, Duncan K. 1996. Structure of UDP-N-Acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-Acetylglucosamine and the drug fosfomycin. Structure 4:1465-1474. https://doi.org/10.1016/S0969-2126(96)00153-0.
6. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. 2010. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 35:240 -243. https://doi.org/10.1016/j.ijantimicag.2009.10.019.
7. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. 2010. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis 10:43-50. https://doi.org/10.1016/S1473-3099(09)70325-1.
8. Gonzalez D, Schmidt S, Derendorf H. 2013. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev 26:274 -288. https://doi.org/10.1128/CMR.00092-12.
9. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 34:506-515. https://doi.org/10.1016/j.ijantimicag.2009.08.013.
10. Viale P, Giannella M, Tedeschi S, Lewis R. 2015. Treatment of MDR-Gram negative infections in the 21st century: A never ending threat for clinicians. Curr Opin Pharmacol 24:30 -37. https://doi.org/10.1016/j.coph.2015.07.001.
11. Chen L, Todd R, Kiehlbauch J, Walters M, Kallen A. 2017. Notes from the field: pan-resistant New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae-Washoe County, Nevada, 2016. MMWR Morb Mortal Wkly Rep 66:33. https://doi.org/10.15585/mmwr.mm6601a7.
12. Infectious Diseases Society of America, Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, Gerding D, Lynfield R, Reller LB, Rex J, Schwartz D, Septimus E, Tenover FC, Gilbert DN. 2011. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52(Suppl 5):S397-S428. https://doi.org/10.1093/cid/cir153.
13. Talbot GH. 2008. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther 6:39-49. https://doi.org/10.1586/14787210.6.1.39.
14. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG, Antimicrobial Availability Task Force of the Infectious Diseases Society of America. 2006. Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42:657- 668. https://doi.org/10.1086/499819.
15. Spellberg B. 2008. Antibiotic resistance and antibiotic development. Lancet Infect Dis 8:211-212. https://doi.org/10.1016/S1473-3099(08)70048-3.
16. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N Engl J Med 368:299 -302. https://doi.org/10.1056/NEJMp1215093.
17. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. 2004. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38:1279 -1286. https://doi.org/10.1086/420937.
18. Nathan C. 2004. Antibiotics at the crossroads. Nature 431:899 -902. https://doi.org/10.1038/431899a.
19. Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J. 2011. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 14:107-117. https://doi.org/10.1016/j.drup.2011.02.005.
20. Walsh CC, McIntosh MP, Peleg AY, Kirkpatrick CM, Bergen PJ. 2015. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 70:3042-3050. https://doi.org/10.1093/jac/dkv221.
21. Parker S, Lipman J, Koulenti D, Dimopoulos G, Roberts JA. 2013. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 42:289-293. https://doi.org/10.1016/j.ijantimicag.2013.05.018.
22. Patel SS, Balfour JA, Bryson HM. 1997. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 53:637- 656.
23. Docobo-Perez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos- Martin V, Ballestero-Tellez M, Rodriguez-Martinez JM, Conejo MC, van Guilder M, Rodriguez-Bano J, Pascual A, Hope WW. 2015. Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance. Antimicrob Agents Chemother 59:5602-5610. https://doi.org/10.1128/AAC.00752-15.
24. Andes D, van Ogtrop ML, Peng J, Craig WA. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 46: 3484-3489. https://doi.org/10.1128/AAC.46.11.3484-3489.2002.
25. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR. 2012. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 56:5916 -5922. https://doi.org/10.1128/AAC.01303-12.
26. Lepak AJ, Andes DR. 2014. Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med 5:a019653. https://doi.org/10.1101/cshperspect.a019653.
27. VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG. 2015. Exploration of the pharmacokineticpharmacodynamic relationships for fosfomycin efficacy using an in vitro infection model. Antimicrob Agents Chemother 59:7170 -7177. https://doi.org/10.1128/AAC.04955-14.
28. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicro-bial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86. https://doi.org/10.1086/510079.
29. Craig WA. 2007. Pharmacodynamics of antimicrobials: general concepts and applications, p 1-22. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. Informa Healthcare USA, Inc, New York, NY.
30. Forest Pharmaceuticals, Inc. 2011. Monurol package insert. Forest Pharmaceuticals, Inc, St. Louis, MO. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/050717s007lbl.pdf.
31. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
32. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
33. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillinclavulanate against Streptococcus pneumoniae: Application to breakpoint determinations. Antimicrob Agents Chemother 42:2375-2379.